Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC.SXTP · Entity 8389 | Director | May 13, 2026 | May 19, 2026 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | March 04, 2026 | April 21, 2026 |
| CervoMed Inc.DFFN · Entity 7338 | Director | June 25, 2021 | October 16, 2021 |
| SCYNEXIS INCSCYX · Entity 7194 | Chief Financial Officer | January 29, 2021 | February 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
60 DEGREES PHARMACEUTICALS, INC.
Report date May 13, 2026 · Filed May 19, 2026
This filing explicitly reported no securities owned.
CERO THERAPEUTICS HOLDINGS, INC.
Report date March 04, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-03-03 | Direct | 1,823,278 |
Reported balance
After 2026-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-04 · Grant · Acquired 1,823,278 · Balance 1,823,278 F1: The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date.
CervoMed Inc.
Report date June 25, 2021 · Filed October 16, 2021
This filing explicitly reported no securities owned.
SCYNEXIS INC
Report date January 29, 2021 · Filed February 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.47 · Expires 2031-01-28 | Direct | 65,000 |
Reported balance
After 2021-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-29 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Apr 21, 2026 23:46 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 1,823,278 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001213900-26-046329 · ownership.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,823,278 Underlying: Common Stock · 1,823,278 shares Expires 2036-03-03 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 01:41 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantRestricted Stock Unit · Derivative | 69,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-016509 · rdgdoc.xml · derivative · entry 3 Francois Eric · CIK 0001656125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,400 Underlying: Common Stock · 69,400 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023. F4 · derivative.expiration_date: The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 01:41 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-016509 · rdgdoc.xml · derivative · entry 2 Francois Eric · CIK 0001656125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F2 · derivative.exercise_date: The shares underlying the options will vest in 18 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over an 18-month period beginning July 1, 2021. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 01:41 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-016509 · rdgdoc.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F1 · derivative.exercise_date: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-21-006716 · doc4.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 300 | Not disclosed Strike: $8.25 | Not disclosed |
DisclosureSEC source: 0001209191-20-064955 · doc4.xml · derivative · entry 3 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2024-06-21 F1 · price: Reflects the purchase on December 21, 2020 of 600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 300 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0001209191-20-064955 · doc4.xml · derivative · entry 2 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2021-12-21 F1 · price: Reflects the purchase on December 21, 2020 of 600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 600 | $6.25 | $3,750.00 |
DisclosureSEC source: 0001209191-20-064955 · doc4.xml · nonDerivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,732 F1 · price: Reflects the purchase on December 21, 2020 of 600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| November 25, 2020 Filed Dec 5, 2020 01:59 UTC | SCYNEXIS INC SCYX · Entity 7194 | Tax withholdingCommon Stock | 3,480 | $6.81 | $23,698.80 |
DisclosureSEC source: 0001209191-20-061878 · doc4.xml · nonDerivative · entry 2 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,132 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations that arose in connection with a vesting event from a restricted stock unit award. F2 · balance_after: Includes 200 shares acquired in 2020 by the reporting person under the Issuer's 2014 Employee Stock Purchase Plan: 100 shares on March 5, 2020 and 100 shares on September 5, 2020. Read SEC document |
| February 15, 2020 Filed Dec 5, 2020 01:59 UTC | SCYNEXIS INC SCYX · Entity 7194 | Tax withholdingCommon Stock | 979 | $9.80 | $9,594.20 |
DisclosureSEC source: 0001209191-20-061878 · doc4.xml · nonDerivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,412 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations that arose in connection with a vesting event from a restricted stock unit award. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:04 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-006273 · doc4.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:52 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-19-011127 · doc4.xml · derivative · entry 2 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-02-14 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:52 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011127 · doc4.xml · nonDerivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,917 F1 · shares: Represents restricted stock units that vest 25% per year over four years. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:49 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 2,662 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-018707 · doc4.xml · derivative · entry 3 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,662 Underlying: Common Stock · 2,662 shares Expires 2023-03-08 F1 · price: Reflects the purchase on March 8, 2018, of 5,917 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:49 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 4,437 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-18-018707 · doc4.xml · derivative · entry 2 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,437 Underlying: Common Stock · 4,437 shares Expires 2019-03-14 F1 · price: Reflects the purchase on March 8, 2018, of 5,917 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:49 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 5,917 | $1.69 | $9,999.73 |
DisclosureSEC source: 0001209191-18-018707 · doc4.xml · nonDerivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,917 F1 · price: Reflects the purchase on March 8, 2018, of 5,917 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-18-009633 · doc4.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 19:23 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001628280-17-000756 · wf-form4_148606341188146.xml · derivative · entry 1 Francois Eric · CIK 0001656125 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: 2.08% of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.